Clinical trials: sponsored by Boehringer Ingelheim
Breast Neoplasms
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
The purpose of the study is to compare the efficacy of treatment with afatinib plus letrozole to treatment with letrozole alone in women diagnosed with a specific type of breast cancer.
- Trial name
- NCT02115048
- Testing
- Letrozole, Afatinib
- Where
- 26 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 44 people
- Sponsor
- Translational Research in Oncology
Scleroderma, Systemic
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality.
- Trial name
- NCT02597933
- Testing
- Nintedanib
- Where
- 195 sites in United States, Argentina and 30 more
- Volunteers
- 580 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Bronchitis
Regulation of the Release of Inflammatory Mediators From Lung Macrophages.
The aim of this study is to investigate the mechanisms whereby specific white cells called macrophages found in the lung release inflammatory mediators or chemicals together with enzymes that destroy the surrounding lung tissue.
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00147017
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Imperial College London
Pulmonary Disease, Chronic Obstructive
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
- Trial name
- NCT02850978
- Testing
- Spiolto
- Where
- Japan
- Volunteers
- 1,335 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effectiveness of Triple Therapy in COPD
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the Long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (LABA-LAMA-ICS) combination with…
- Trial name
- NCT03724877
- Testing
- Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS), Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)
- Where
- United Kingdom
- Volunteers
- 8,853 people
- Sponsor
- Boehringer Ingelheim
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
- Trial name
- NCT03188120
- Testing
- Spiriva Respimat
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects
The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of BI 443651 in male and female healthy volunteers and subjects with Cystic Fibrosis (CF).
- Trial name
- NCT02976519
- Testing
- BI 443651
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
BI 443651 Methacholine Challenge
The primary objective of this study is to investigate safety and tolerability of three consecutive administrations, 12 hours apart, at three different dose-levels of BI 443651 administered via oral inhalation in male and female…
- Trial name
- NCT03135899
- Testing
- BI 443651
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
The primary objective of the study is to investigate the relative bioavailability of Movalis capsules 15 mg (Test, T) versus Movalis tablets 15 mg (Reference, R).
- Trial name
- NCT03684265
- Testing
- Meloxicam Capsule (Test), Meloxicam Tablet (Reference)
- Where
- Russia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Colorectal Neoplasms
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable).
- Trial name
- INVICTAN®-3 (NCT02776683)
- Testing
- BI 695502, Avastin
- Where
- 46 sites in United States, Japan and 2 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment.
- Trial name
- NCT02203851
- Testing
- Risankizumab
- Volunteers
- 110 people
- Sponsor
- AbbVie
Healthy
Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects
This trial will investigate the pharmacokinetics and safety of BI 695502 and to establish pharmacokinetic biosimilarity of BI 695502 compared to bevacizumab.
- Trial name
- NCT01608087
- Testing
- BI 695502, bevacizumab
- Where
- 2 sites in New Zealand
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypertension
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in…
- Trial name
- NCT00946829
- Testing
- telmisartan
- Where
- 12 sites in Belgium, Canada and 10 more
- Volunteers
- 18,299 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)
- Trial name
- NCT02839746
- Where
- Spain
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD), Emphysema
The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
This is an observational study examining outcomes and treatment patterns in a community-based cohort of subjects with Chronic obstructive pulmonary disease (COPD) who are based in the Kannapolis, NC area.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT02838108
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Duke University
Auricular Fibrillation, Anticoagulant Drugs
Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year
- Trial name
- NCT04133545
- Where
- Argentina
- Volunteers
- 360 people
- Sponsor
- Hospital Italiano de Buenos Aires
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Hematoma
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery.
- Trial name
- BRUISECONTROL2 (NCT01675076)
- Testing
- Dabigatran, Rivaroxaban, Apixaban
- Where
- 15 sites in Canada, Israel
- Volunteers
- 663 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Diabetes Mellitus, Type 2
PMS of Trazenta on the Long-term Use as Add-on Therapy
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.
- Trial name
- NCT01904383
- Testing
- Trazenta
- Where
- Japan
- Volunteers
- 4,057 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Sequential Expansion of Comparative Effectiveness of Anticoagulants
This cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database…
- Trial name
- NCT02081807
- Where
- United States
- Volunteers
- 221,228 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.